Jeena Sikho Lifecare Limited has informed the Exchange regarding Change in Auditors of the company.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of Jeena Sikho Lifecare Limited met on May 30, 2026, and approved the audited standalone and consolidated financial results for FY 2025-26. Standalone revenue from operations stood at Rs. 8,013.46 crore, with profit before tax of Rs. 2,978.75 crore and profit after tax of Rs. 2,221.76 crore — more than doubling compared to the previous year (PBT was Rs. 1,075.78 crore in FY 2024-25). Basic EPS improved to Rs. 17.87 from Rs. 6.43 year-on-year. The Board recommended a final dividend of Rs. 4.50 per share (face value Rs. 2), subject to shareholder approval at the ensuing AGM. The statutory audit was conducted by Walker Chandiok & Co LLP (new auditor), replacing KRA & Co. who audited the previous year, with an unmodified opinion. The internal auditor, Forvis Mazars LLP, was re-appointed for FY 2026-27. The company operates across two segments: Ayurvedic products/medicines and Ayurvedic healthcare services.
Strong financial performance with near doubling of profits year-on-year reflects operational scale-up. Dividend payout signals confidence. The change in statutory auditors from KRA & Co. to Walker Chandiok & Co LLP may attract market attention but an unqualified opinion is positive.